---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-008034"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T13:04:12.863443+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown

## Summary
- Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.
- Raised over $5M in funding; access to Lincoln Park equity line of up to $10M.
- Added two key executives with pharmaceutical drug development experience to management.
- Filed patent application for novel breath-propelled intranasal delivery device.
- Developed nanoparticle spray-dried formulation in partnership with UK partner under GMP.

## SEC filing metadata
- accession: 0001683168-22-008034
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/0001683168-22-008034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-008034
- JSON: https://secwatch.observer/filing/0001683168-22-008034.json
- Plain text: https://secwatch.observer/filing/0001683168-22-008034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.